Study S000502

A Phase 1, Randomized, Open-label, Parallel-group, Drug-drug Interaction Study to Evaluate the Effect of Antiemetic Medication on the Pharmacokinetics of AMG 133 in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07310563
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 59
Start: 2024-12-10
Primary completion: 2025-05-09
Lead sponsor: Amgen
Conditions: Overweight; Obesity
Interventions: DRUG:AMG 133; DRUG:Ondansetron
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Maximum Observed Plasma Concentration (Cmax) of AMG 133 [Up to Day 120]
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120]
AUC from Time Zero to Infinity (AUCinf) of AMG 133 [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.